J. B. Chemicals & Pharmaceuticals Limited

Press Release

BSE Scrip Code: 506943 **NSE Symbol: JBCHEPHARM**

Mumbai, July 29, 2011: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its unaudited financial results for quarter ended June 2011. The highlights of these results are as under:

STANDALONE RESULTS FOR Q1:

(Rs. in crores)

Net Sales	**177.44**	**Up 11.69 % Y-o-Y**
PBT	**26.88**	**Up 8.93% Y-o-Y**
PAT	**19.04**	**Down 7.95 % Y-o-Y**
EPS (Rs.)(FV Rs. 2)	**2.25**	

During the quarter, the domestic formulations sales registered reasonable growth. The focus products marketing strategy in this business has consistently resulted into favourable products mix. The rest of the world business continued its growth streak with growth of 26% over the same quarter last year. The company is in discussion with South African Pharma majors for newer long term contract manufacturing opportunity.

The increase in field force in domestic formulations business including launch of new dedicated division catering to gynecology and dental segment with over 100 medical representatives and increase in R&D strength contributed to higher staff cost during the quarter. The company considers these as investment and would help the company generate higher sales in future.

The Russia-CIS business sales were almost the same as those in the same quarter last year. The Russia-CIS OTC products business has now vested in Cilag GmbH International, a wholly owned subsidiary of Johnson & Johnson, w.e.f. July 14, 2011 consequent to closure of the sale transaction. The company has also entered into an agreement with Dr. Reddy's Laboratories Ltd. for sale of the company's Russia-CIS prescription products business. This transaction is expected to close in the current quarter.

The company is now fully focused on growth of domestic formulations, Rest of the world and contract manufacturing businesses for future growth.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in South Africa, other South African Countries, and South-East Asian countries. The company continues to focus on growing its share in the regulated markets of US, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS & Formulations and sound regulatory capabilities for filing of DMFs, ANDAs and similar product registration documents. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:
This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.